Why Nurix Therapeutics Stock Soared More Than 21% Wednesday

Why Nurix Therapeutics Stock Soared More Than 21% Wednesday

The clinical-stage biopharmaceutical company posted positive news regarding its lead therapy -- a BTK inhibitor that could fight certain blood-based cancers.